Windtree Therapeutics Inc Stock Price, News & Analysis

Windtree Therapeutics (WINT) has announced a transformative acquisition of Titan Environmental Services, marking its entry into the $85 billion US waste management market. The deal involves issuing preferred shares and securing debt financing, with Titan becoming a subsidiary renamed as Windtree Environmental Services. The acquisition is expected to generate $12 million in revenue over the next 12 months and includes an $8 million breakup fee protection. The company plans to retain Titan's management team and pursue a roll-up strategy in the fragmented waste management industry. This move represents a strategic shift for Windtree, which is actively seeking to divest or partner its pharmaceutical assets to reduce costs and increase profitability. The transaction is anticipated to close in Q3 2025.

Aditxt (ADTX) has appointed Evofem Biosciences CEO Saundra Pelletier to its Board of Directors. Pelletier brings over three decades of pharmaceutical industry experience, specializing in women's health. During her 10-year leadership at Evofem, she successfully led the company's public market transition and oversaw the approval of PHEXXI, a hormone-free contraceptive gel, and SOLOSEC, an antibiotic for bacterial infections. Her appointment aligns with Aditxt's strategy to expand into women's health monitoring, prevention, and treatment. Pelletier's extensive background includes roles at Woman Care Global and G.D. Searle, and she currently serves on multiple boards including Windtree Therapeutics.

Windtree Therapeutics (WINT) announced its Board of Directors has approved the development of a cryptocurrency policy that will enable the company to accept cryptocurrency payments and hold them as strategic assets. The biotechnology company, which is transitioning to become revenue-generating, is in discussions with several Bitcoin-focused groups regarding payment options and treasury strategy. CEO Jed Latkin indicated that the policy development is aligned with digital commerce trends and will be completed in the near term. The initiative is part of Windtree's broader corporate strategy to generate revenue while maintaining its focus on innovative therapies for critical conditions.

Windtree Therapeutics (WINT) has announced that interim analysis results for its istaroxime SEISMiC SCAI Stage C Phase 2 study in cardiogenic shock are targeted for July 2025. The global trial, conducted across the U.S., Europe, and Latin America, is evaluating istaroxime as an addition to standard care treatments. The study is placebo-controlled and double-blinded, with the primary endpoint focusing on systolic blood pressure profile during the first six hours of treatment. The trial will assess various metrics including cardiac function, vasopressor-inotrope score, progression prevention to more severe stages, and patient recovery indicators. This study follows two previously completed positive Phase 2 studies in SCAI Stage B cardiogenic shock and represents a crucial step toward advancing to Phase 3 trials.

Windtree Therapeutics (NASDAQ: WINT) announced the presentation of istaroxime data from their SEISMiC Extension Phase 2b study at the European Society of Cardiology Heart Failure 2025 Conference in Belgrade. The presentation, focusing on the safety and efficacy of intravenous istaroxime for pre-cardiogenic shock patients over 60-hour periods, will be delivered by Dr. Jan Biegus from Wroclaw Medical University. Dr. Steve Simonson, Windtree's CMO, highlighted the positive study results as crucial for advancing istaroxime to Phase 3 trials. The company believes istaroxime's unique profile distinguishes it from existing therapies for treating cardiogenic shock, a condition associated with high mortality, morbidity, and healthcare costs.

Windtree Therapeutics (WINT) reported Q1 2025 financial results and strategic updates. The company posted an operating loss of $4.1 million, compared to $4.4 million in Q1 2024. Key highlights include:

The company is pursuing a new strategy to become revenue-generating through: - Acquiring FDA-approved assets - A right to purchase a 436-unit residential property in Houston - Partnership for PHEXXI® manufacturing cost reduction - China partnership expected to generate revenues by end of 2026

Financial position shows cash and cash equivalents of $1.2 million with current liabilities of $6.5 million. The company raised $2.6 million through Series D convertible preferred stock in April-May 2025. Notably, Windtree regained Nasdaq compliance but remains under monitoring until March 2026.

Windtree Therapeutics (NASDAQ: WINT) announced the presentation of preclinical data on istaroxime and a selective SERCA2a activator at the upcoming European Society of Cardiology Heart Failure Conference. The ePoster presentation demonstrates how istaroxime and its metabolite analog (CVie216) help reduce calcium-dependent arrhythmias in an STZ rat model during ischemia-reperfusion by activating SERCA2a.

The study identified a potential mechanism explaining the decreased incidence of reperfusion-induced arrhythmias in STZ-isolated hearts after exposure to these compounds. This research is particularly significant as arrhythmias can severely impact heart function and can be fatal, especially in patients with heart failure and cardiomyopathy.

Windtree Therapeutics (NASDAQ: WINT) has announced potential U.S. exclusivity strategies for its drug candidate istaroxime in treating cardiogenic shock. If granted New Chemical Entity (NCE) designation by the FDA, istaroxime could receive 7.5 years of U.S. market exclusivity upon approval. The company also holds a U.S. method of use patent extending protection until 2039, with a pending patent that could provide coverage until 2043.

The company is currently conducting the SEISMiC C Phase 2 study, a global placebo-controlled trial evaluating istaroxime in SCAI Stage C cardiogenic shock patients. The study's primary endpoint focuses on systolic blood pressure profile over 6 hours of treatment, with an interim analysis planned for Q3 2025.

Windtree Therapeutics (WINT) has entered an Assignment and Conditional Assumption Agreement to acquire a 436-unit multifamily residential property in Houston, Texas. This strategic move marks a shift in the company's strategy to become revenue-generating while continuing its biotech pipeline development. The acquisition, planned for May 23, 2025, will be primarily funded through non-recourse secured mortgage financing and preferred stock issuance.

The company has the option to extend the closing date for two 30-day periods. The deal is contingent upon satisfactory due diligence and financing terms. Windtree's new corporate strategy includes acquiring revenue-generating assets, including small biotech companies with FDA-approved products, while maintaining its focus on cardiovascular and oncology drug development.